1
|
Li X, Xu C, Liang B, Kastelic JP, Han B, Tong X, Gao J. Alternatives to antibiotics for treatment of mastitis in dairy cows. Front Vet Sci 2023; 10:1160350. [PMID: 37404775 PMCID: PMC10315858 DOI: 10.3389/fvets.2023.1160350] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 05/26/2023] [Indexed: 07/06/2023] Open
Abstract
Mastitis is considered the costliest disease on dairy farms and also adversely affects animal welfare. As treatment (and to a lesser extent prevention) of mastitis rely heavily on antibiotics, there are increasing concerns in veterinary and human medicine regarding development of antimicrobial resistance. Furthermore, with genes conferring resistance being capable of transfer to heterologous strains, reducing resistance in strains of animal origin should have positive impacts on humans. This article briefly reviews potential roles of non-steroidal anti-inflammatory drugs (NSAIDs), herbal medicines, antimicrobial peptides (AMPs), bacteriophages and their lytic enzymes, vaccination and other emerging therapies for prevention and treatment of mastitis in dairy cows. Although many of these approaches currently lack proven therapeutic efficacy, at least some may gradually replace antibiotics, especially as drug-resistant bacteria are proliferating globally.
Collapse
Affiliation(s)
- Xiaoping Li
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Chuang Xu
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Bingchun Liang
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - John P. Kastelic
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada
| | - Bo Han
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Xiaofang Tong
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Jian Gao
- Department of Clinical Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, China
| |
Collapse
|
2
|
de Jong E, McCubbin KD, Speksnijder D, Dufour S, Middleton JR, Ruegg PL, Lam TJGM, Kelton DF, McDougall S, Godden SM, Lago A, Rajala-Schultz PJ, Orsel K, De Vliegher S, Krömker V, Nobrega DB, Kastelic JP, Barkema HW. Invited review: Selective treatment of clinical mastitis in dairy cattle. J Dairy Sci 2023; 106:3761-3778. [PMID: 37080782 DOI: 10.3168/jds.2022-22826] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 01/01/2023] [Indexed: 04/22/2023]
Abstract
Treatment of clinical mastitis (CM) and use of antimicrobials for dry cow therapy are responsible for the majority of animal-defined daily doses of antimicrobial use (AMU) on dairy farms. However, advancements made in the last decade have enabled excluding nonsevere CM cases from antimicrobial treatment that have a high probability of cure without antimicrobials (no bacterial causes or gram-negative, excluding Klebsiella spp.) and cases with a low bacteriological cure rate (chronic cases). These advancements include availability of rapid diagnostic tests and improved udder health management practices, which reduced the incidence and infection pressure of contagious CM pathogens. This review informed an evidence-based protocol for selective CM treatment decisions based on a combination of rapid diagnostic test results, review of somatic cell count and CM records, and elucidated consequences in terms of udder health, AMU, and farm economics. Relatively fast identification of the causative agent is the most important factor in selective CM treatment protocols. Many reported studies did not indicate detrimental udder health consequences (e.g., reduced clinical or bacteriological cures, increased somatic cell count, increased culling rate, or increased recurrence of CM later in lactation) after initiating selective CM treatment protocols using on-farm testing. The magnitude of AMU reduction following a selective CM treatment protocol implementation depended on the causal pathogen distribution and protocol characteristics. Uptake of selective treatment of nonsevere CM cases differs across regions and is dependent on management systems and adoption of udder health programs. No economic losses or animal welfare issues are expected when adopting a selective versus blanket CM treatment protocol. Therefore, selective CM treatment of nonsevere cases can be a practical tool to aid AMU reduction on dairy farms.
Collapse
Affiliation(s)
- Ellen de Jong
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1; One Health at UCalgary, University of Calgary, AB, Canada T2N 4N1; Mastitis Network, Saint-Hyacinthe, QC, Canada J25 2M2
| | - Kayley D McCubbin
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1; One Health at UCalgary, University of Calgary, AB, Canada T2N 4N1; Mastitis Network, Saint-Hyacinthe, QC, Canada J25 2M2
| | - David Speksnijder
- Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, the Netherlands; University Animal Health Clinic ULP, 3481 LZ Harmelen, the Netherlands
| | - Simon Dufour
- Mastitis Network, Saint-Hyacinthe, QC, Canada J25 2M2; Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada J2S 2M2
| | - John R Middleton
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia 65211
| | - Pamela L Ruegg
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824
| | - Theo J G M Lam
- Department Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, the Netherlands; GD Animal Health, 7400 AA Deventer, the Netherlands
| | - David F Kelton
- Mastitis Network, Saint-Hyacinthe, QC, Canada J25 2M2; Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada N1G 2W1
| | - Scott McDougall
- Cognosco, Anexa, Morrinsville 3340, New Zealand; School of Veterinary Science, Massey University, Palmerston North 4442, New Zealand
| | - Sandra M Godden
- Department of Veterinary Population Medicine, University of Minnesota, St. Paul 55108
| | | | - Päivi J Rajala-Schultz
- Department of Production Animal Medicine, Faculty of Veterinary Medicine, 00014 University of Helsinki, Finland
| | - Karin Orsel
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1
| | - Sarne De Vliegher
- M-team and Mastitis and Milk Quality Research Unit, Department of Internal Medicine, Reproduction and Population Health, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium
| | - Volker Krömker
- Section for Animal Production, Nutrition and Health, Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg, Denmark
| | - Diego B Nobrega
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1; One Health at UCalgary, University of Calgary, AB, Canada T2N 4N1
| | - John P Kastelic
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1
| | - Herman W Barkema
- Faculty of Veterinary Medicine, University of Calgary, Calgary, AB, Canada T2N 4N1; One Health at UCalgary, University of Calgary, AB, Canada T2N 4N1; Mastitis Network, Saint-Hyacinthe, QC, Canada J25 2M2.
| |
Collapse
|
3
|
de Jong E, Creytens L, De Vliegher S, McCubbin KD, Baptiste M, Leung AA, Speksnijder D, Dufour S, Middleton JR, Ruegg PL, Lam TJGM, Kelton DF, McDougall S, Godden SM, Lago A, Rajala-Schultz PJ, Orsel K, Krömker V, Kastelic JP, Barkema HW. Selective treatment of nonsevere clinical mastitis does not adversely affect cure, somatic cell count, milk yield, recurrence, or culling: A systematic review and meta-analysis. J Dairy Sci 2023; 106:1267-1286. [PMID: 36543640 DOI: 10.3168/jds.2022-22271] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 09/18/2022] [Indexed: 12/24/2022]
Abstract
Treatment of clinical mastitis (CM) contributes to antimicrobial use on dairy farms. Selective treatment of CM based on bacterial diagnosis can reduce antimicrobial use, as not all cases of CM will benefit from antimicrobial treatment, e.g., mild and moderate gram-negative infections. However, impacts of selective CM treatment on udder health and culling are not fully understood. A systematic search identified 13 studies that compared selective versus blanket CM treatment protocols. Reported outcomes were synthesized with random-effects models and presented as risk ratios or mean differences. Selective CM treatment protocol was not inferior to blanket CM treatment protocol for the outcome bacteriological cure. Noninferiority margins could not be established for the outcomes clinical cure, new intramammary infection, somatic cell count, milk yield, recurrence, or culling. However, no differences were detected between selective and blanket CM treatment protocols using traditional analyses, apart from a not clinically relevant increase in interval from treatment to clinical cure (0.4 d) in the selective group and higher proportion of clinical cure at 14 d in the selective group. The latter occurred in studies co-administering nonsteroidal anti-inflammatories only in the selective group. Bias could not be ruled out in most studies due to suboptimal randomization, although this would likely only affect subjective outcomes such as clinical cure. Hence, findings were supported by a high or moderate certainty of evidence for all outcome measures except clinical cure. In conclusion, this review supported the assertion that a selective CM treatment protocol can be adopted without adversely influencing bacteriological and clinical cure, somatic cell count, milk yield, and incidence of recurrence or culling.
Collapse
Affiliation(s)
- Ellen de Jong
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada; Mastitis Network, St-Hyacinthe, Quebec, J25 2M2 Canada
| | - Lien Creytens
- M-team and Mastitis and Milk Quality Research Unit, Department of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, 9820 Belgium
| | - Sarne De Vliegher
- M-team and Mastitis and Milk Quality Research Unit, Department of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, 9820 Belgium
| | - Kayley D McCubbin
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada; Mastitis Network, St-Hyacinthe, Quebec, J25 2M2 Canada
| | - Mya Baptiste
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
| | - Alexander A Leung
- Departments of Medicine and Community Health Science, Cumming School of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
| | - David Speksnijder
- Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, 3508 TD, the Netherlands; University Farm Animal Practice, Harmelen, 3481 LZ, the Netherlands
| | - Simon Dufour
- Mastitis Network, St-Hyacinthe, Quebec, J25 2M2 Canada; Department of Pathology and Microbiology, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, J2S 2M2 Canada
| | - John R Middleton
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia 65211
| | - Pamela L Ruegg
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824
| | - Theo J G M Lam
- Department Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, 3584 CL, the Netherlands; GD Animal Health, Deventer, 7400 AA, the Netherlands
| | - David F Kelton
- Mastitis Network, St-Hyacinthe, Quebec, J25 2M2 Canada; Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1 Canada
| | - Scott McDougall
- Cognosco, Anexa, Morrinsville, 3340 New Zealand; School of Veterinary Science, Massey University, Palmerston North, 4442 New Zealand
| | - Sandra M Godden
- Department of Veterinary Population Medicine, University of Minnesota, St. Paul 55108
| | | | - Päivi J Rajala-Schultz
- Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, 00014 Finland
| | - Karin Orsel
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
| | - Volker Krömker
- Section for Animal Production, Nutrition and Health, Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg, Denmark
| | - John P Kastelic
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada
| | - Herman W Barkema
- Faculty of Veterinary Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada; Mastitis Network, St-Hyacinthe, Quebec, J25 2M2 Canada; Departments of Medicine and Community Health Science, Cumming School of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1 Canada.
| |
Collapse
|
4
|
Yu Y, Yang Q, Wang Z, Ding Q, Li M, Fang Y, He Q, Zhu YZ. The Anti-Inflammation and Anti-Nociception Effect of Ketoprofen in Rats Could Be Strengthened Through Co-Delivery of a H 2S Donor, S-Propargyl-Cysteine. J Inflamm Res 2021; 14:5863-5875. [PMID: 34785926 PMCID: PMC8590460 DOI: 10.2147/jir.s333326] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 10/11/2021] [Indexed: 01/20/2023] Open
Abstract
PURPOSE Ketoprofen (KETO) is a traditional non-steroidal anti-inflammatory drug (NSAIDs) with good analgesic and antipyretic effects. However, as NASIDs, the toxicity of KETO towards gastrointestinal (GI) system might limit its clinical use. S-propargyl-cysteine (SPRC) is an excellent endogenous H2S donor showed wide application in the field of anti-inflammation, anti-oxidative stress, or even the protection of cardiovascular system through the elevation of endogenous H2S concentration. As recently studies reported, co-administration of H2S donor might potentially mitigate the GI toxicity and relevant side effects induced by series of NSAIDs. METHODS In this study, we established a SPRC and KETO co-encapsulated poly (lactic-co-glycolic acid) microsphere (SK@MS), and its particle size, morphology, storage stability and in vitro release profile were firstly investigated. The elevation of endogenous H2S level of SK@MS was then calculated, and the pharmacodynamic study (anti-inflammation and analgesic effects) of SK@MS, SPRC, and KETO towards adjuvant induced arthritis (AIA) in rats were also studied. Finally, to test the potential side effect, the heart, liver, spleen, lung, kidney, stomach, small intestine, and large intestine were resected from rats and examined by H&E staining. RESULTS A monodispersed SK@MS could be observed under the SEM, and particle size was calculated around 25.12 μm. The loading efficiency (LE) for SPRC and KETO were 6.67% and 2.64%, respectively, while the encapsulation efficiency (EE) for SPRC and KETO were 37.20% and 68.28%, respectively. SK@MS showed a sustained release of SPRC and KETO in vitro, which was up-to 15 days. SK@MS could achieve a long-term elevation of the H2S concentration in vivo, while SPRC showed an instant H2S elevation and metabolize within 6 h. Interestingly, the KETO did not show any influence on the H2S concentration in vivo. After establishment of AIA model, neither SPRC nor KETO showed scarcely anti-inflammation and anti-nociception effect, while conversely, SK@MS showed an obvious mitigation towards paw edema and pain in AIA rats, which indicated an improved anti-inflammation and anti-nociception effect when co-delivery of SRC and KETO. Besides, low stimulation towards major organs in rats observed in any experimental group. CONCLUSION A monodispersed was successfully prepared in this study, and SK@MS showed a sustained SPRC and KETO release in vitro and H2S release in vivo. In the pharmacodynamics study, SK@MS not only exhibited an excellent anti-inflammation and analgesic effects in AIA rats but also showed low stimulation towards rats.
Collapse
Affiliation(s)
- Yue Yu
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Qinyan Yang
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Zhou Wang
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Qian Ding
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Meng Li
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Yudong Fang
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Qida He
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
| | - Yi Zhun Zhu
- State Key Laboratory of Quality Research in Chinese Medicine & School of Pharmacy, Macau University of Science and Technology, Taipa, Macau SAR, People's Republic of China
- Shanghai Key Laboratory of Bioactive Small Molecules & School of Pharmacy, Fudan University, Shanghai, People's Republic of China
| |
Collapse
|
5
|
Ketoprofen Combined with UVA Irradiation Exerts Higher Selectivity in the Mode of Action against Melanotic Melanoma Cells than against Normal Human Melanocytes. Int J Mol Sci 2021; 22:ijms222111966. [PMID: 34769396 PMCID: PMC8584642 DOI: 10.3390/ijms222111966] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Revised: 11/01/2021] [Accepted: 11/02/2021] [Indexed: 12/20/2022] Open
Abstract
Malignant melanoma is responsible for the majority of skin cancer-related deaths. The methods of cancer treatment include surgical removal, chemotherapy, immunotherapy, and targeted therapy. However, neither of these methods gives satisfactory results. Therefore, the development of new anticancer therapeutic strategies is very important and may extend the life span of people suffering from melanoma. The aim of this study was to examine the effect of ketoprofen (KTP) and UVA radiation (UVAR) therapy on cell proliferation, apoptosis, and cell cycle distribution in both melanotic melanoma cells (COLO829) and human melanocytes (HEMn-DP) in relation to its supportive effect in the treatment of melanoma. The therapy combining the use of pre-incubation with KTP and UVAR causes a significant increase in the anti-proliferative properties of ketoprofen towards melanoma cells and the co-exposure of melanotic melanoma cells induced apoptosis shown as the mitochondrial membrane breakdown, cell-cycle deregulation, and DNA fragmentation. Moreover, co-treatment led to GSH depletion showing its pro-apoptotic effect dependent on ROS overproduction. The treatment did not show a significant effect on normal cells—melanocytes—which indicates its high selectivity. The results suggest a possible benefit from the use of the ketoprofen and ultraviolet A irradiation as a new concept of melanotic melanoma therapy.
Collapse
|
6
|
Ruegg PL. What Is Success? A Narrative Review of Research Evaluating Outcomes of Antibiotics Used for Treatment of Clinical Mastitis. Front Vet Sci 2021; 8:639641. [PMID: 33604368 PMCID: PMC7884469 DOI: 10.3389/fvets.2021.639641] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 01/08/2021] [Indexed: 11/13/2022] Open
Abstract
Treatment of clinical mastitis is the most common reason that antimicrobials are given to adult dairy cows and careful consideration of treatment protocols is necessary to ensure responsible antimicrobial stewardship. Clinical mastitis is caused by a variety of bacteria which stimulate an immune response that often results in spontaneous bacteriological clearance but can develop into long-term subclinical infections. Use of antimicrobial therapy is most beneficial for cases that are caused by pathogens that have a low rate of spontaneous cure but high rate of therapeutic cure. The purpose of this paper is to review studies that evaluated outcomes of antimicrobial therapy of clinical mastitis. Few studies reported differences in bacteriological cure among treatments and this outcome was rarely associated with clinical outcomes. Return to normal milk appearance was evaluated in most studies but demonstrated little variation and is not a reliable indicator of therapeutic success. Somatic cell count should be measured at quarter-level and will decline gradually after bacteriological clearance. Few researchers have evaluated important clinical outcomes such as post-treatment milk yield or culling. Few differences among approved antimicrobial therapies have been demonstrated and selection of antimicrobial therapy should consider the spectrum of activity relative to etiology.
Collapse
Affiliation(s)
- Pamela L Ruegg
- David J. Ellis Chair in Antimicrobial Resistance & Professor of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, United States
| |
Collapse
|